Meeting
2021 ASCO Annual Meeting
Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Authors
Van K. Morris II
The University of Texas MD Anderson Cancer Center, Houston, TX
Van K. Morris II, Greg Yothers , Scott Kopetz , Samuel A. Jacobs , Peter C. Lucas , Atif Iqbal , Patrick M Boland , Dustin A. Deming , Aaron James Scott , Howard John Lim , Norman Wolmark , Thomas J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Clinical Trial Registration Number
NCT04068103
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3622)
DOI
10.1200/JCO.2021.39.15_suppl.TPS3622
Abstract #
TPS3622
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
First Author: Van K. Morris II
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
First Author: Van K. Morris II
Poster
2023 ASCO Annual Meeting
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
First Author: Van K. Morris II
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
First Author: Van K. Morris II